In this study, we observed an increase of the CD4 + T cells and CD4/CD8 ratio in the SIB group but not in the non-SIB group after CIRT, suggesting that higher doses had the potential to induce more powerful tumor cytotoxicity and tumor antigen release, which were beneficial to CD4 + T-cell activation and expansion. The gene discussed is CD4; the disease is neoplasm.